Condition: Biliary Tract Cancers (BTC) · Sponsor: Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Unresectable BTC represents an area of unmet medical need due to its very aggressive nature, limited treatment options, and poor prognosis. This study is to evaluate the efficacy and safety of adding TTF to the established regimen of durvalumab plus GemCis for the treatment of patients with previously untreated, unresectable BTC.
This description comes directly from the study's public registry record.
Lianxin Liu · 0551-96512 · liulx@ustc.edu.cn
Always discuss trial participation with your own doctor first.
| Anhui Provincial Hospital | Hefei, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06611345